Takeda ends DNL593 collaboration; Denali regains full rights
Takeda walked away from an eight-year partnership. The patients stayed.
Denali Therapeutics announced on April 3 that Takeda has terminated its collaboration on DNL593, an investigational therapy for frontotemporal dementia driven by granulin gene mutations (FTD-GRN), returning full rights to Denali. The decision was driven by strategic considerations, the companies said, and was not related to efficacy or safety data.
DNL593 is a progranulin replacement therapy delivered using Denali's TransportVehicle platform — the technology that earned the company the first FDA approval for a blood-brain barrier-crossing biologic, a milestone that was supposed to be a commercial anchor. The therapy is designed to restore progranulin levels in patients whose mutations cause the protein to be deficient, driving neurodegeneration. There are currently no approved medications to slow or stop FTD progression.
The Phase 1/2 trial is ongoing with 40 enrolled FTD-GRN patients. Denali expects to report results by the end of 2026. Interim data from the healthy volunteer portion showed dose-dependent increases in cerebrospinal fluid progranulin levels, consistent with robust brain delivery. No significant safety signals have emerged. In short: the drug is doing what the science predicted, and the trial is still running.
"While we have greatly valued our partnership, we are pleased to regain full ownership of DNL593," said Ryan Watts, Denali's CEO. "We remain confident in the scientific rationale and the data generated to date, and we look forward to advancing DNL593 independently."
Takeda declined to elaborate beyond the phrase "strategic considerations." That phrasing typically means a program does not fit a company's current portfolio priorities — a category that has grown broader as large pharma has retrenched around fewer therapeutic areas and fewer late-stage assets. The timing is notable: the decision arrives roughly two years after Takeda made a series of neuroinflammation pipeline cuts and just as several competitors have moved aggressively into neurodegeneration.
The TransportVehicle platform deserves separate attention. It is not an unproven concept awaiting validation — it is FDA-approved and generating royalty revenue from its first commercial product. That credibility did not insulate DNL593 from Takeda's strategic calculus. Platforms do not retain partners on their own; the asset does.
Denali regains full control of the intellectual property and the trial. The Phase 1/2 readout remains on track for the end of 2026. Forty patients are still enrolled. The science continues regardless of who owns the commercial rights.